Overview

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Status:
Completed
Trial end date:
2017-04-11
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products, R&D Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Calcitonin
Calcitonin Gene-Related Peptide
Immunoglobulins
Katacalcin